Necroptosis Identifies Novel Molecular Phenotypes and Influences Tumor Immune Microenvironment of Lung Adenocarcinoma
Open Access
- 14 July 2022
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 13, 934494
Abstract
This study aims to investigate the immune and epigenetic mutational landscape of necroptosis in lung adenocarcinoma (LUAD), identify novel molecular phenotypes, and develop a prognostic scoring system based on necroptosis regulatory molecules for a better understanding of the tumor immune microenvironment (TIME) in LUAD. Based on the Cancer Genome Atlas and Gene Expression Omnibus database, a total of 29 overlapped necroptosis-related genes were enrolled to classify patients into different necroptosis phenotypes using unsupervised consensus clustering. We systematically correlated the phenotypes with clinical features, immunocyte infiltrating levels, and epigenetic mutation characteristics. A novel scoring system was then constructed, termed NecroScore, to quantify necroptosis of LUAD by principal component analysis. Three distinct necroptosis phenotypes were confirmed. Two clusters with high expression of necroptosis-related regulators were “hot tumors”, while another phenotype with low expression was a “cold tumor”. Molecular characteristics, including mutational frequency and types, copy number variation, and regulon activity differed significantly among the subtypes. The NecroScore, as an independent prognostic factor (HR=1.086, 95%CI=1.040-1.133, p<0.001), was able to predict the survival outcomes and show that patients with higher scores experienced a poorer prognosis. It could also evaluate the responses to immunotherapy and chemotherapeutic efficiency.In conclusion, necroptosis-related molecules are correlated with genome diversity in pan-cancer, playing a significant role in forming the TIME of LUAD. Necroptosis phenotypes can distinguish different TIME and molecular features, and the NecroScore is a promising biomarker for predicting prognosis, as well as immuno- and chemotherapeutic benefits in LUAD.Keywords
This publication has 45 references indexed in Scilit:
- Methylation-dependent loss of RIP3 expression in cancer represses programmed necrosis in response to chemotherapeuticsCell Research, 2015
- Comprehensive molecular profiling of lung adenocarcinomaNature, 2014
- Mechanisms underlying mutational signatures in human cancersNature Reviews Genetics, 2014
- The mechanism of necroptosis in normal and cancer cellsCancer Biology & Therapy, 2013
- Clinical significance of down-regulated cylindromatosis gene in chronic lymphocytic leukemiaLeukemia & Lymphoma, 2013
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in CancerNew England Journal of Medicine, 2012
- Hallmarks of Cancer: The Next GenerationCell, 2011
- The Receptor Interacting Protein 1 Inhibits p53 Induction through NF-κB Activation and Confers a Worse Prognosis in GlioblastomaCancer Research, 2009
- Lung adenocarcinoma invasion in TGFβRII-deficient cells is mediated by CCL5/RANTESOncogene, 2007
- The morphology of apoptosisCell and tissue research, 2000